Welcome to our dedicated page for VSee Health news (Ticker: VSEE), a resource for investors and traders seeking the latest updates and insights on VSee Health stock.
VSee Health, Inc. (NASDAQ: VSEE) is a telehealth technology and services company whose news flow centers on AI-powered virtual care, digital health infrastructure, and capital markets developments. As a health information services provider, VSee regularly issues updates on its telehealth platform, AI initiatives, hospital partnerships, and regulatory milestones, giving investors and healthcare stakeholders insight into how the business is evolving.
Company press releases highlight product and solution launches, such as the AI-enhanced Rural Health Transformation Solution designed for rural hospitals, and initiatives that apply VSee’s configurable digital health infrastructure to specialty access, clinical workflows, and financial performance. News items also cover collaborations with health systems on tele-urgent care, teleradiology, telenursing, and high-acuity virtual care programs, as well as international projects in regions like Southeast Asia where VSee’s platform supports maternal health, primary care, and tuberculosis screening efforts.
VSEE news frequently addresses AI and security credentials, including references to FedRAMP High Authority to Operate from the U.S. Department of Health and Human Services and FedRAMP Moderate authorization related to federal telehealth deployments. These updates help readers understand how VSee positions its telehealth and AI infrastructure for hospital systems, health networks, employers, and government partners.
In addition, VSee’s news feed includes financial and corporate disclosures that complement its SEC filings, such as announcements of private placements, equity line arrangements, convertible notes, and Nasdaq listing compliance updates. Readers following VSEE news can track how the company’s technology initiatives, service contracts, and financing activities intersect, and can return to this page to review new releases as they are published.
VSee Health (NASDAQ: VSEE) has entered into a non-binding letter of intent to acquire certain healthcare technology and operating assets that support an integrated healthcare commerce platform serving the U.S. clinic-based wellness market. The contemplated acquisition is valued at approximately $42 million and, according to VSee, the target assets have an unaudited annual revenue run rate in excess of $35 million and EBITDA of about $7 million. The company states the deal is expected to close fairly quickly and without initial shareholder dilution.
The platform connects suppliers, commercial organizations and clinics via cloud-based ordering, payment workflows and coordinated back-office operations, while suppliers retain product and fulfillment responsibilities. VSee believes the assets could complement its API-driven virtual care platform and form part of its broader strategic review aimed at accelerating growth and strengthening its competitive position. The LOI is non-binding (other than customary provisions), and any transaction remains subject to due diligence, definitive agreements, approvals and customary closing conditions, with no assurance of completion.
VSee Health (NASDAQ:VSEE) entered into a non-binding letter of intent to acquire certain healthcare technology and operating assets that support a vertically integrated healthcare commerce platform for the U.S. clinic-based wellness market. The proposed acquisition is valued at approximately $42 million.
According to VSee, the target assets have an unaudited annual revenue run rate in excess of $35 million and EBITDA of about $7 million. The platform links suppliers, commercial organizations and clinics via provider-facing sales, cloud-based ordering and payment workflows, and supplier coordination, while maintaining an asset-light model in which regulated parties retain product and fulfillment responsibilities.
VSee believes the contemplated deal could complement its API-driven virtual care platform and aligns it with the company’s ongoing strategic review aimed at accelerating growth and enhancing long-term stockholder value. Completion of any transaction remains subject to due diligence, definitive agreements, approvals and customary closing conditions, and there is no assurance it will close.
VSee Health (NASDAQ:VSEE) announced that its Board of Directors has initiated a comprehensive strategic review to evaluate a broad range of alternatives intended to accelerate growth and maximize long-term shareholder value. The company is in late-stage discussions with potential strategic partners and is considering options such as strategic partnerships, business combinations, mergers, acquisitions, licensing transactions, capital formation initiatives and other strategic opportunities.
The Board aims to select the alternative it believes offers the greatest potential value for shareholders, while management continues executing the current business strategy. VSee cautions there is no assurance the review will result in any transaction, and it does not plan to provide further updates unless a specific transaction is approved or further disclosure is required.
VSee Health (NASDAQ:VSEE) announced that its board approved a proposed reverse stock split of up to 80-for-1, subject to regulatory and shareholder approvals, to better align its capital structure and support continued Nasdaq listing. The company clarified that the previously referenced maximum ratio of up to 250-for-1 has been corrected to no more than 80-for-1.
According to VSee Health, it has terminated its previously announced standby equity purchase agreement and currently has no active equity financing facility expected to cause near-term dilution. As of July 6, 2026, the company had 55,679,813 common shares outstanding and reports using non-dilutive financing over the past 45 days while seeking to minimize shareholder dilution and preserve long-term value.
VSee Health (Nasdaq: VSEE) outlined its vision for AI-enabled enterprise infrastructure as the next phase of hospital operations, positioning its iDoc telehealth platform as a core operating layer rather than a standalone application. Management sees AI supporting efficiency and experience for patients and providers.
According to the company, its hospital network grew from 3 hospitals in 2024 to 58 in 2026, with 100% of operating revenue now coming from the focused iDoc enterprise platform. VSee reports gross margins exceeding 50%, approximately 50% annual revenue growth, and positioning for an approximately $20 million revenue run-rate, supported by streamlined operations after the separation of VSee Lab and increasing demand for integrated, AI-ready enterprise infrastructure.
VSee Health (NASDAQ:VSEE) issued a CEO shareholder update outlining its strategic shift toward the iDoc TeleHealth Solutions business. Hospital deployments expanded from 3 to 58 in three years, supported by the divestiture of lab operations to cut costs and sharpen focus.
Management highlights expanding hospital adoption, accelerating revenue growth and improving operating leverage, and anticipates the iDoc TeleHealth business can reach profitability within 12 months based on current plans and internal expectations.
VSee Health (NASDAQ:VSEE) reported a 20-fold expansion of its hospital network to 58 locations, up from 3 over about two years. This expansion supported 2025 revenue of $11.4 million, an 80% increase. VSee focuses on enterprise telehealth via Integrated Delivery Network relationships and multi-year deployments.
According to VSee, the company aims for a $20 million annual revenue run-rate, sustained gross margins of at least 50%, and progress toward profitability as it targets reach into hundreds of hospitals over the next two years.
VSee Health (NASDAQ:VSEE) outlined business performance after the May 31, 2026 strategic sale of VSee Lab and renewed focus on its iDoc telehealth platform and enterprise healthcare solutions.
Pro-forma results show 2025 revenue up 60% to $8 million and Q1 2026 revenue up 70% to $2.5 million, alongside an approximate $6 million annual reduction in operating expenses.
Several large multi-year IDN contracts signed in 2025 are ramping and expanding telehealth services. Management believes targeting $20 million revenue and profitability over the next 12 months is realistic, citing improved margins and lower operating costs.
VSee Health (NASDAQ:VSEE) completed a strategic separation from its former lab subsidiary, VSee Lab, selling 100% of VSee Lab to former Co-CEO and Chairman Milton Chen.
Chen returned 2,870,069 VSee shares (about 7% of outstanding), which will be retired, and assumed remaining VSee Lab liabilities. Dr. Imoigele Aisiku becomes sole CEO and Chairman, with VSee Health focusing on its iDoc telehealth platform, enterprise healthcare solutions, AI-enabled care, and recurring revenue opportunities.
VSee Health (Nasdaq:VSEE) reported full-year 2025 results with revenue up 40% to $14,618,184 and a materially stronger balance sheet after debt-to-equity conversions. Cash and equivalents rose to $5,266,286 at year-end. The company said operating expenses fell sharply and management expects continued contract-driven growth in 2026.
The company noted multi-year institutional contracts (including a previously announced $10 million per year deal), FedRAMP High approval for VSee Labs, and ongoing telehealth rollouts across multiple states.